| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0008 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.0009 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.001 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.094 | 0.002 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.13 | 0.002 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.16 | 0.003 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.13 | 0.003 |
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | -0.096 | 0.004 |